Landau In Der Pfalz

Researchers are comparing personalized cognitive-behavioral therapy (CBT) using network analysis with standardized CBT in treating adults with chronic primary pain (CPP). CPP is a condition where pain persists for at least six months and significantly impacts daily functioning. This study aims to see if personalized CBT, which tailors treatment based on individual data, can improve outcomes compared to the usual standardized approach. The trial includes patients from German outpatient clinics and evaluates treatment effects on pain-related disability and other psychological factors. Participants undergo two types of CBT interventions: a personalized CBT that starts with 21 days of intensive ecological momentary assessment (EMA) to identify key pain processes and targets specific therapy modules, and a standardized CBT consisting of five sessions based on a short manual including techniques like relaxation and cognitive strategies. The study uses a single-case experimental design with randomized baseline phases where participants receive both interventions in different orders, separated by baseline periods and followed by an EMA phase and booster therapy sessions. During the study, participants complete various questionnaires measuring pain disability, therapy expectations, side effects, therapeutic alliance, and psychological distress before, during, and after treatment phases, including a follow-up three months later. Data are collected frequently during some phases to capture changes over time. Researchers analyze outcomes at both individual and group levels to understand the effectiveness of each CBT approach. The total participation involves multiple phases over several months including booster sessions to support long-term effects.

Researchers are evaluating the effectiveness and safety of a subcutaneous cladribine treatment for patients with hairy cell leukemia who need therapy. This study focuses on patients who are either untreated or have only been pretreated with alpha-interferon. It aims to assess remission rates four months after treatment and whether a second cycle benefits those with a non-optimal response, defined by residual disease or partial remission. Participants receive cladribine 0.14 mg/kg as a subcutaneous bolus injection once daily for five consecutive days. If the response after the first cycle is not optimal, patients may receive a second cycle of the drug to improve their remission status. This treatment approach is being studied in a Phase 2/3 clinical trial setting. During the study, remission status is evaluated four months after the first treatment cycle. Patients undergo assessments to detect residual disease in bone marrow and peripheral blood. Researchers monitor the rate of complete remissions and any treatment-related toxicities. The overall health, laboratory tests, and disease markers are regularly checked throughout the study period to ensure safety and to measure the treatment's impact.